Nice numbers at 20: what end-of-life evidence does NICE draw on?NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend Share XNice numbers at 20: what end-of-life evidence does NICE draw on?https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-what-end-of-life-evidence-does-nice-draw-on/
Q&A: Sangamo’s Duncan McKay on genomic medicinesWe talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future Share XQ&A: Sangamo’s Duncan McKay on genomic medicineshttps://pharmaphorum.com/views-analysis-market-access/qa-sangamos-duncan-mckay-on-genomic-medicines/
Innovative contracting in Europe: a Trojan Horse?By Mary Iyiola & Agnieszka Janska, with additional consultation by Smita Sealey & Barry Farrimond In a recent Share XInnovative contracting in Europe: a Trojan Horse?https://pharmaphorum.com/views-analysis-market-access/innovative-contracting-in-europe-a-trojan-horse-2/
Navigating emerging markets – opportunities and challenges for pharmaThe pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of Share XNavigating emerging markets – opportunities and challenges for pharmahttps://pharmaphorum.com/views-analysis-market-access/navigating-emerging-markets-opportunities-and-challenges-for-pharma/
Q&A: Adaptimmune’s Elliot Norry on cell therapyDr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing Share XQ&A: Adaptimmune’s Elliot Norry on cell therapyhttps://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/
Biosimilars in the UK: where are we now and where does the NHS want to go?The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges Share XBiosimilars in the UK: where are we now and where does the NHS want to go?https://pharmaphorum.com/views-analysis-market-access/biosimilars-in-the-uk/
From supplier to partner – how industry can work better with the new-look NHSA move towards integrated care systems (ICS), complete with new primary care roles, and a greater focus on Share XFrom supplier to partner – how industry can work better with the new-look NHShttps://pharmaphorum.com/views-analysis-market-access/from-supplier-to-partner-how-industry-can-work-better-with-the-new-look-nhs/
NICE numbers at 20: trends in dealsNICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends Share XNICE numbers at 20: trends in dealshttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/
NICE numbers at 20 – a closer look at cancerThere has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Share XNICE numbers at 20 – a closer look at cancerhttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/
